CHIR 98014

Biological Activity

CHIR 98014 is a highly potent and selective GSK-3 inhibitor (IC₅₀ values are 0.58 and 0.65 nM for the β and α isoforms, respectively). Exhibits >500-fold selectivity for GSK-3β over a range of other kinases. Improves insulin sensitivity of muscle strips from diabetic rats in vitro and decreases insulin and glucose levels in the oral glucose tolerance test in vivo. Activates Wnt signaling in human adipose stem cells (hASC) and promotes the production of definitive endoderm. Has been used in protocols to derive epicardial cells from hPSCs.

Technical Data

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.

Background References

1. Selective glycogen synthase kinase 3 inhibitors potentiate Ins activation of glucose transport and utilization in vitro and in vivo.
   Ring et al.
   Diabetes, 2003;52:588
2. Simply derived epicardial cells.
   Paik and Wu et al.
   Nat.Biomed.Eng., 2017;1
3. Activation of Wnt/β-catenin signalling via GSK3 inhibitors direct differentiation of human adipose stem cells into functional hepatocytes.
   Huang et al.
   Sci.Rep., 2017;7:40716

Product Datasheets